Supernus Pharmaceuticals, a global drugmaker with an estimated $4 billion in sales, has been under scrutiny for the past several years.
The company has been the subject of scrutiny from government regulators and Congress for its sales practices, including a potential connection to the opioid crisis.
It is one of the largest pharmaceutical companies in the world, with a market value of more than two trillion dollars.
Supernus shares were up 1.7 percent to $40.19 on Thursday in New York.
The company had been trading at $39.10 in a Reuters index of stocks.